Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCl, in metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Estrogen Antagonists
  • Piperidines
  • Thiophenes

abstract

  • As predicted in preclinical testing, daily oral LY353381.HCl is safe, is well tolerated at all tested dose levels, and may be clinically beneficial in patients with extensively pretreated metastatic breast cancer. Further studies with LY353381 to evaluate the efficacy in patients with or without prior exposure to tamoxifen and fewer overall prior regimens are under way.

publication date

  • April 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11283133

Additional Document Info

start page

  • 2002

end page

  • 9

volume

  • 19

number

  • 7